1. Scrip
  2. >>Business

Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks

 
• By Anju Ghangurde

The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.

Bottles coronavirus vaccine. sars-cov-2 / COVID-19. Some ampoules with ncov-2019 vaccine in a box. to fight the coronavirus pandemic.
Past Outbreaks Provide Lessons To Help Scale-Up Vaccine Manufacturing • Source: Shutterstock

As vaccines for COVID-19 dash towards the finish line, companies have in parallel had to work at break-neck speed to scale up at-risk manufacturing of the candidates to ensure that they can be delivered quickly once approved.

Vaccine manufacturing can be extremely complex and German multinational Merck KGaA has been collaborating on various fronts, including on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 
• By Alaric DeArment

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By Mandy Jackson

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By Andy Smith

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.